Haemostatic function, arterial disease and the prevention of arterial thrombosis.
Recent years have seen the expansion of information linking raised plasma levels of individual clotting factors and evidence of disturbances of fibrinolytic activity with the risk of thrombotic manifestations of arterial disease, both in community-based, apparently healthy populations and in patients with known atherosclerosis. Some of these prothrombotic changes in the haemostatic system may result partly from underlying chronic inflammation or acute infection and may, in turn, contribute substantially to the thrombotic risk which accompanies these underlying processes. The importance of the coagulation system in the pathogenesis of arterial thrombosis is further illustrated by the benefit in the Thrombosis Prevention Trial of low-intensity, dose-adjusted warfarin in the primary prevention of ischaemic heart disease. Clinical trials of bezafibrate, which is being used for its fibrinogen-lowering as well as lipid-modifying properties, are in progress.
MacCallum
P K
PK
Department of Haematology, St Bartholomew's and The Royal London School of Medicine and Dentistry, UK.
Meade
T W
TW
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000453:epidemiology / Q000503:physiopathology* / Q000517:prevention & control; D001779:Blood Coagulation Factors / Q000378:metabolism / Q000494:pharmacology; D002986:Clinical Trials as Topic; D019468:Disease Management; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D011446:Prospective Studies; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control; D013927:Thrombosis / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control*
D000925:Anticoagulants; D001779:Blood Coagulation Factors